Related Experiment Video
Updated: Jul 14, 2026

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
Published on: March 6, 2018
[Treatment of hormonal refractory metastatic prostate cancer]
Lisa Sengeløv1, Ole Peter Klarskov, Stellan Karlsson
1Herlev Hospital, Onkologisk Afdeling, Herlev. lisa.sengelov@dadlnet.dk
Abstract:
Hormonal refractory metastatic prostate cancer is a fatal disease with a poor prognosis. Treatment options are palliative with second line anti-hormonal, estrogens and prednisolon. When palliation is the goal, the side effects have to be carefully considered. Local radiotherapy has an effective pain relieving effect, and can be repeated. Chemotherapy with docetaxel and prednisolon is indicated in patients with symptomatic metastatic disease. Newer options with immunotherapy and designed molecules have not yet proven effective. Pain and anemia are significant symptoms and should be treated in a multidisciplinary setting.
Related Concept Videos
Treatment Resistent Cancers
Treatment Resistant Cancers
Targeted Cancer Therapies
There are several types of targeted therapies against specific...

